Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Cardiogenics Holdings,
Inc.
(OTC:CGNH)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
Digital
Angel Corporation
(AMEX:DOC)
Dynavax Technologies
Corporation
(NASDAQ:DVAX)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware Information Systems, Inc. (NASDAQ: MEDW)
Redpoint Bio Corporation
(OTC:RPBC)
| Access Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes propriety products for the treatment and supportive care of cancer patients. Its products include ProLindac, which is in Phase II clinical testing of patients with ovarian cancer; and MuGard for the management of patients with mucositis, a debilitating side effect of various anticancer treatments. The company also has other advanced drug delivery technologies, including Cobalamin-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax, a non-toxic prodrug that is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. In addition, Access Pharmaceuticals is developing Phenylbutyrate, an HDAC inhibitor and differentiating agent that is a Phase II clinical candidate. The company, through its subsidiary, MacroChem Corporation, offers three late-stage product candidates: Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection; EcoNail, a topically applied econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus; and Thiarabine, a nucleoside analog which demonstrated pre-clinical and clinical activity in certain cancers. Access Pharmaceuticals offers MuGard in Germany, Italy, the United Kingdom, Greece, and the Nordic countries by its European commercial partner, SpePharm Holding, B.V. The company was founded in 1988 and is based in Dallas, Texas. |